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The immune system is crucial toprotect organisms from a varietyof pathogens, including bacteria,
viruses and fungi. However, the devel-
opment and function of immune cells
need to be tightly controlled in order to
avoid reactivity against the host, which
is termed autoimmunity. A variety of
common diseases, including rheuma-
toid arthritis, multiple sclerosis (MS)
and inflammatory bowel disease (IBD)
are caused by an overshooting activity
of the immune system and inflamma-
tory reactions. Many drugs commonly
used to suppress the immune system
in those patients like corticosteroids
which act in a very general way and
have significant side effects when long-
term treatment is required. Despite
major advances over the last few
years, there is still a demand for thera-
peutic strategies targeting specific
components of the immune system. 
In this context, it was an important
finding that certain intramembrane
proteases, which are druggable
enzymes and can be targeted by small
molecule inhibitors, control the devel-
opment and function of certain
immune cells. Intramembrane pro-
tease represent enzymes embedded
in cellular membranes which can
cleave the transmembrane domain of
membrane-spanning substrate pro-
teins (for more details see the October
2018 edition of Open Access Govern-
ment). One of these intramembrane
proteases is Signal peptide peptidase-
like 2a (SPPL2a) which is localised in
the membrane of lysosomes, an 
intracellular compartment involved in
degradation of proteins and other
macromolecules. With its ability to
cleave transmembrane proteins,
SPPL2a contributes essentially to the
turnover of these proteins. 
Although the discovery and character-
isation of further SPPL2a substrates is
still ongoing, one substrate of partic-
ular importance in immune cells is 
the CD74 protein which has several
well-established functions in B 
lymphocytes and dendritic cells (DCs).
Whereas the latter are particularly
important to recognise invading
pathogens, B cells produce antibodies
targeting the “intruders” which is a
major mechanism to clear infections.
A specific step in the degradation of
the CD74 protein requires intramem-
brane proteolysis by SPPL2a. There-
fore, in absence of the protease a
small, membrane-embedded fragment
of CD74 massively accumulates in B
cells and DCs and disturbs their devel-
opment and function. SPPL2a defi-
ciency in mice results in a major
impairment of both cell types and in
humans, it causes increased suscepti-
bility to infections with mycobacteria
like tuberculosis (TB). The reduced 
ability of humans with mutations in the
SPPL2a gene to fight mycobacterial
infections can be explained by a loss of
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specific DCs, which are required to trig-
ger immune responses against these
pathogens. Thus, the presence of
SPPL2a and its ability to degrade CD74
represents an important checkpoint in
B cells and DCs. The dependence of
these cells on SPPL2a may allow to
deplete them in patients with SPPL2a
specific inhibitors, which could be ben-
eficial in different disease contexts like
MS or Systemic lupus erythematosus
(SLE) and represents an interesting
novel concept.
Besides ensuring the proper matura-
tion of immune cells, it is also impor-
tant to tightly control their number,
since the unrestricted proliferation of,
for instance, B cells results in diseases
like multiple myeloma. One protein
that is involved in the regulation of B
cell survival is the B-cell maturation
antigen (BCMA). It is expressed on the
surface of B cells and is cleaved by the
γ-secretase complex that contains the
intramembrane protease presenilin as
an active subunit (for more details see
July 2019 edition of Open Access Gov-
ernment). The inhibition of this cleav-
age results in accumulation of BCMA
and an increased number of B cells in
the bone marrow, indicating that an
intramembrane protease is critically
involved in an immunoregulatory
mechanism to limit B cells in bone
marrow and most likely also in plasma.
SPPL3, another intramembrane pro-
tease and homologue of SPPL2a, is
crucial for normal development of
Natural Killer cells (NK cells). NK cells
are part of the innate immune system
and critical for tumour surveillance as
well as clearance of virally infected
cells. After development in the bone
marrow, NK cells migrate and popu-
late all organs of the body where 
they undergo final maturation steps
and become fully active “guardians”.
Deficiency of SPPL3 in mice results in
impaired maturation of NK cells and
reduced clearance of tumour cells. This
makes SPPL3 an interesting player in
the immune system and in tumour
defence. However, before SPPL3 is con-
sidered as a therapeutic target, it needs
to be further investigated if it is indeed
dysregulated in immune deficiencies or
malignant tumours.
As these examples show, several
intramembrane proteases play pivotal
roles in specific immune cells. It seems
that their activity represents critical
checkpoints which these cells need to
bypass in order to differentiate and
become functionally mature. Certainly,
the mechanisms involved in the differ-
entiation processes will require further
work to understand them at the
molecular level. But previous research
has unambiguously shown that defin-
ing the action of intramembrane pro-
teases in immune cells will increase
our general understanding of how we
fight infections and the way in which
this may be exploited to control an
over-activated immune system. 
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The intramembrane proteases SPPL2a as a novel target for therapeutic immunosuppression,
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